Characterization of a unique patient cohort with spike-wave activation in sleep without cognitive decline or increased seizure burden: Considerations for a more conservative treatment approach

IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY
Rene Andrade Machado , Jennifer Meylor , Shruti L. Narayan , Natalie B. Norton
{"title":"Characterization of a unique patient cohort with spike-wave activation in sleep without cognitive decline or increased seizure burden: Considerations for a more conservative treatment approach","authors":"Rene Andrade Machado ,&nbsp;Jennifer Meylor ,&nbsp;Shruti L. Narayan ,&nbsp;Natalie B. Norton","doi":"10.1016/j.seizure.2025.03.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The goal of this study is to better characterize a unique subset of patients who present with so-called “isolated SWAS” (Spike Wave Activation in Sleep) by analyzing electrographic and neuropsychological data.</div></div><div><h3>Methods</h3><div>We evaluated our institution's population of patients with SWAS, defined as &gt;/= 50 % spike-wave index potentiated during slow-wave sleep. Of this group, 26 patients were identified with no worsening cognitive performance or seizure burden at the time of diagnosis, deemed “isolated SWAS”, in comparison to patients with Developmental and/or Epileptic Encephalopathy (D/EE)-SWAS. Paraclinical studies of this cohort were analyzed, including high-frequency oscillations, specifically on scalp electroencephalogram as well as comprehensive behavioral and neuropsychologic data at one-year follow-up.</div></div><div><h3>Results</h3><div>We found that 80 % (n=21) of the cohort was started on a unique treatment for SWAS at the time of diagnosis, with the most common treatment being clobazam (n=12; 57 %) followed by valproic acid (n=9; 43 %). The cognitive performance of patients who received treatment and those who did not receive treatment was not statistically significant, and after one year of follow-up the patients who did not receive treatment for SWAS had no cognitive decline. Furthermore, the treatment group reported more medication side effects (n=14/21; 67 %). Seven patients (27 %) of the cohort continued to have SWAS at follow-up, and 11 patients (42 %) had ongoing seizures. The presence of ripples did not correlate with cognitive outcomes.</div></div><div><h3>Significance</h3><div>This study suggests that if patients have “isolated-SWAS” at the time of diagnosis a more conservation approach may be considered.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"127 ","pages":"Pages 115-126"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seizure-European Journal of Epilepsy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1059131125000573","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The goal of this study is to better characterize a unique subset of patients who present with so-called “isolated SWAS” (Spike Wave Activation in Sleep) by analyzing electrographic and neuropsychological data.

Methods

We evaluated our institution's population of patients with SWAS, defined as >/= 50 % spike-wave index potentiated during slow-wave sleep. Of this group, 26 patients were identified with no worsening cognitive performance or seizure burden at the time of diagnosis, deemed “isolated SWAS”, in comparison to patients with Developmental and/or Epileptic Encephalopathy (D/EE)-SWAS. Paraclinical studies of this cohort were analyzed, including high-frequency oscillations, specifically on scalp electroencephalogram as well as comprehensive behavioral and neuropsychologic data at one-year follow-up.

Results

We found that 80 % (n=21) of the cohort was started on a unique treatment for SWAS at the time of diagnosis, with the most common treatment being clobazam (n=12; 57 %) followed by valproic acid (n=9; 43 %). The cognitive performance of patients who received treatment and those who did not receive treatment was not statistically significant, and after one year of follow-up the patients who did not receive treatment for SWAS had no cognitive decline. Furthermore, the treatment group reported more medication side effects (n=14/21; 67 %). Seven patients (27 %) of the cohort continued to have SWAS at follow-up, and 11 patients (42 %) had ongoing seizures. The presence of ripples did not correlate with cognitive outcomes.

Significance

This study suggests that if patients have “isolated-SWAS” at the time of diagnosis a more conservation approach may be considered.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Seizure-European Journal of Epilepsy
Seizure-European Journal of Epilepsy 医学-临床神经学
CiteScore
5.60
自引率
6.70%
发文量
231
审稿时长
34 days
期刊介绍: Seizure - European Journal of Epilepsy is an international journal owned by Epilepsy Action (the largest member led epilepsy organisation in the UK). It provides a forum for papers on all topics related to epilepsy and seizure disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信